Arcus Biosciences, Inc.
https://www.arcusbio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Arcus Biosciences, Inc.
Finance Watch: Zenas, Bicara, MBX Aim To Raise $100m Or More In Future IPOs
Fifteen biopharma firms have launched IPOs in the US this year, but three more have joined the queue. Also, Galderma sold CHF500m ($590.7m) in bonds to pay down debt, Noetik raised a $40m series A round and ImCheck collected €20.18m ($22.4m) from the French government.
Arcus Borrows $250m Despite Having $1bn In The Bank
A loan from Hercules Capital will fund Phase III development of renal cancer drug casdatifan, perhaps signaling low expectations of a Gilead opt-in.
Asia Deal Watch: Orum, Vertex Team Up On Gene Editing Conditioning Agents
Plus deals involving Eisai/Sato, Keymed/Belenos, Taiho/Arcus, IASO/Innovent, Biocytogen/SOTIO, Ensol/Spine, TMS/Hokkaido University and Yuhan/Ubix.
Merck Hits Brakes On Anti-PD-1/TIGIT Study In Adjuvant Melanoma
Industry-wide, the combination of PD-1/PD-L1 inhibitors with TIGIT inhibitors has produced a mixed bag in terms of results.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice